Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy: the PREVENT single-centre, randomised, controlled trial
- 1 October 1999
- journal article
- clinical trial
- Published by Elsevier in The Lancet
- Vol. 354 (9189) , 1493-1498
- https://doi.org/10.1016/s0140-6736(99)09405-2
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Cell cycle inhibition preserves endothelial function in genetically engineered rabbit vein grafts.Journal of Clinical Investigation, 1997
- The retinoblastoma protein and cell cycle controlCell, 1995
- Femoropopliteal-crural graft patency is improved by an intensive surveillance program: A prospective randomized studyPublished by Elsevier ,1995
- Pharmacokinetics of antisense oligodeoxyribonucleotides (cyclin B1 and CDC 2 kinase) in the vessel wall in vivo: enhanced therapeutic utility for restenosis by HVJ-liposome deliveryGene, 1994
- Intimal hyperplasia after vascular injury is inhibited by antisense cdk 2 kinase oligonucleotides.Journal of Clinical Investigation, 1994
- Human saphenous vein grafts explanted from the arterial circulation demonstrate altered smooth-muscle and endothelial responsesJournal of Vascular Surgery, 1993
- Stranger in a strange land: The pathogenesis of saphenous vein graft stenosis with emphasis on structural and functional differences between veins and arteriesProgress in Cardiovascular Diseases, 1991
- Proliferating or interleukin 1-activated human vascular smooth muscle cells secrete copious interleukin 6.Journal of Clinical Investigation, 1990
- Functional Abnormalities of Experimental Autogenous Vein Graft NeoendotheliumAnnals of Surgery, 1988
- The Relation of Risk Factors to the Development of Atherosclerosis in Saphenous-Vein Bypass Grafts and the Progression of Disease in the Native CirculationNew England Journal of Medicine, 1984